Myeloid‐resident neuropilin‐1 promotes choroidal neovascularization while mitigating inflammation
Elisabeth M. M. A. Andriessen, François Binet, Frédérik Fournier, Masayuki Hata, Agnieszka Dejda, Gaëlle Mawambo, Sergio Crespo‐Garcia, Frédérique Pilon, Manuel Buscarlet, Karine Beauchemin, Véronique Bougie, Garth Cumberlidge, Ariel M. Wilson, Steve Bourgault, Flávio Rezende, Normand Beaulieu, Jean‐Sébastien Delisle, Przemysław Sapieha
Abstract
Age-related macular degeneration (AMD) in its various forms is a leading cause of blindness in industrialized countries. Here, we provide evidence that ligands for neuropilin-1 (NRP1), such as Semaphorin 3A and VEGF-A, are elevated in the vitreous of patients with AMD at times of active choroidal neovascularization (CNV). We further demonstrate that NRP1-expressing myeloid cells promote and maintain CNV. Expression of NRP1 on cells of myeloid lineage is critical for mitigating production of inflammatory factors such as IL6 and IL1β. Therapeutically trapping ligands of NRP1 with an NRP1-derived trap reduces CNV. Collectively, our findings identify a role for NRP1-expressing myeloid cells in promoting pathological angiogenesis during CNV and introduce a therapeutic approach to counter neovascular AMD.